investment_code,investment_name,company_name,company_id,fund_name,fund_id,investment_date,initial_investment_amount,initial_investment_currency,total_invested_amount,total_invested_currency,ownership_percentage,investment_type,investment_stage,sector,geography,board_seats,liquidation_preference,anti_dilution_protection,drag_along_rights,tag_along_rights,investment_thesis,key_risks,exit_strategy,target_exit_date,created_date,last_modified_date
PM-INV-001,TechFlow Solutions Growth Capital Fund III,TechFlow Solutions,PM-COMP-001,Growth Capital Fund III,FUND-001,2022-08-15,25000000,USD,25000000,USD,15.5,Equity,Growth,Technology,North America,1,1.0x Non-Participating Preferred,Weighted Average Broad-Based,Yes,Yes,Leading SaaS platform with strong recurring revenue and expansion into new verticals,Customer concentration and competitive pressure,Strategic Sale or IPO,2027-08-15,2022-08-01,2024-01-15
PM-INV-002,RetailMax Holdings Growth Capital Fund III,RetailMax Holdings,PM-COMP-004,Growth Capital Fund III,FUND-001,2022-11-20,50000000,USD,50000000,USD,65.2,Equity,Buyout,Consumer,North America,3,1.0x Non-Participating Preferred,Full Ratchet,Yes,Yes,Market consolidation opportunity with experienced management team,E-commerce disruption and changing consumer preferences,Strategic Sale,2027-11-20,2022-11-01,2024-01-20
PM-INV-003,CloudSoft Systems Growth Capital Fund III,CloudSoft Systems,PM-COMP-011,Growth Capital Fund III,FUND-001,2023-05-10,30000000,USD,30000000,USD,45.8,Equity,Buyout,Technology,North America,2,1.0x Participating Preferred,Weighted Average Narrow-Based,Yes,Yes,Enterprise cloud migration tailwinds with strong competitive moat,Technology disruption and customer churn,Strategic Sale or IPO,2028-05-10,2023-04-25,2024-01-24
PM-INV-004,MedDevice Innovations European Buyout Fund II,MedDevice Innovations,PM-COMP-002,European Buyout Fund II,FUND-002,2022-09-25,15000000,EUR,15000000,EUR,55.3,Equity,Buyout,Healthcare,Europe,2,1.0x Non-Participating Preferred,Weighted Average Broad-Based,Yes,Yes,Regulatory moats and aging population demographics,Regulatory changes and reimbursement pressure,Strategic Sale,2027-09-25,2022-09-10,2024-01-22
PM-INV-005,European Pharma European Buyout Fund II,European Pharma,PM-COMP-012,European Buyout Fund II,FUND-002,2022-12-15,18000000,EUR,18000000,EUR,12.8,Equity,Co-Investment,Healthcare,Europe,0,1.0x Non-Participating Preferred,Pro Rata,No,Yes,Specialty pharma with rare disease focus and pipeline,Patent cliff and regulatory approval risks,Strategic Sale,2027-12-15,2022-12-01,2024-01-15
PM-INV-006,BioTech Ventures Healthcare Innovation Fund I,BioTech Ventures,PM-COMP-009,Healthcare Innovation Fund I,FUND-003,2023-04-20,8000000,USD,8000000,USD,22.5,Equity,Growth,Healthcare,North America,1,1.0x Participating Preferred,Weighted Average Broad-Based,Yes,Yes,AI-powered drug discovery with promising oncology pipeline,Clinical trial risks and regulatory approval timeline,IPO or Strategic Sale,2028-04-20,2023-04-05,2024-01-22
PM-INV-007,FinTech Innovations Healthcare Innovation Fund I,FinTech Innovations,PM-COMP-005,Healthcare Innovation Fund I,FUND-003,2023-08-30,10000000,USD,10000000,USD,18.7,Equity,Growth,Financial Services,Asia Pacific,1,1.0x Non-Participating Preferred,Weighted Average Broad-Based,Yes,Yes,Digital banking platform with strong SME focus in underserved market,Regulatory uncertainty and competitive pressure,Strategic Sale,2028-08-30,2023-08-15,2024-01-28
PM-INV-008,Infrastructure Debt Portfolio Infrastructure Debt Fund,Infrastructure Debt Portfolio,INFRA-001,Infrastructure Debt Fund,FUND-004,2021-02-28,80000000,USD,80000000,USD,15,Equity,Growth,Infrastructure,North America,1,1.0x Non-Participating Preferred,Weighted Average Broad-Based,Yes,Yes,Diversified infrastructure debt portfolio with stable cash flows,Interest rate risk and refinancing risk,Strategic Sale,2029-02-28,2021-02-15,2024-01-18
PM-INV-009,AgriTech Solutions Asia Pacific Growth Fund,AgriTech Solutions,PM-COMP-013,Asia Pacific Growth Fund,FUND-006,2022-11-30,22000000,USD,22000000,USD,28.3,Equity,Growth,Agriculture,North America,1,1.0x Non-Participating Preferred,Weighted Average Broad-Based,Yes,Yes,Precision agriculture technology with strong IP and growing market,Weather dependency and adoption challenges,Strategic Sale or IPO,2027-11-30,2022-11-15,2024-01-26